Gibson, Dunn & Crutcher represented XOMA Corporation in the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Daré. XOMA Corporation (NASDAQ: XOMA) announced...
You must be a Standard 1 Year member to access this content.
XOMA was represented by Gibson, Dunn & Crutcher LLP. XOMA Corporation (NASDAQ: XOMA) announced it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for a...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised XOMA Corporation on the expansion of its commercial royalty and milestone portfolio with the acquisition of an economic interest in...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Xoma Corporation on the deal. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator announced its multi-license and milestone monetization transaction with Viracta Therapeutics....
You must be a Standard 1 Year member to access this content.
